English, Article edition: Cost-Efficacy Analysis of Fluticasone Propionate versus Zafirlukast in Patients with Persistent Asthma Rogelio Menendez; Richard H. Stanford; Lisa Edwards; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/93647
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost-Efficacy Analysis of Fluticasone Propionate versus Zafirlukast in Patients with Persistent Asthma
Author
  • Rogelio Menendez
  • Richard H. Stanford
  • Lisa Edwards
  • Christopher Kalberg
  • Kathleen Rickard
Physical Description
  • article
Notes
  • Objective: To compare the relative value of an inhaled corticosteroid, fluticasone propionate 88microg twice daily, versus an oral leukotriene receptor antagonist, zafirlukast 20mg twice daily, in patients with persistent asthma currently receiving short acting beta2-agonists alone. Study design: A cost-efficacy analysis using resource utilisation and clinical data obtained prospectively from a multicentre, randomised, double-blind, double-dummy, placebo-controlled 12-week clinical trial conducted in the US. Perspective: Third-party payor. Patients and methods: A total of 451 corticosteroid-naive patients with persistent asthma were treated with either fluticasone propionate 88microg twice daily or zafirlukast 20mg twice daily. All patients were given salbutamol (albuterol) to be used as rescue medication. Data were examined using intent-to-treat analysis. Results: Mean daily per person cost-efficacy ratios using improvement in forced expiratory volume in 1 second (FEV1) [>=​12% increase from baseline] were $US3.47 for fluticasone propionate compared with $US7.81 for zafirlukast (1999 values). The mean daily per person cost-efficacy ratios for symptom-free days obtained were $US5.51 for fluticasone propionate compared with $US14.98 for zafirlukast. These cost-efficacy ratios remained in favour of fluticasone propionate after a robust sensitivity analysis. Conclusions: Treatment with fluticasone propionate 88microg twice daily was the most cost effective treatment compared with zafirlukast 20mg twice daily in this 12-week clinical trial. This analysis supports the use of fluticasone propionate 88microg twice daily as first-line treatment in patients with persistent asthma previously treated with short-acting beta2-agonist alone.
  • Antiasthmatics, Asthma, Cost effectiveness, Fluticasone propionate, Pharmacoeconomics, Zafirlukast
  • RePEc:wkh:phecon:v:19:y:2001:i:8:p:865-874
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment